/
Explanatory Note From August 23, 2013 to December 6, 2020, Synaptogenix, Inc. (formerly known as Neurotrope Bioscience, Inc.) (the Company or Synaptogenix ) was a wholly owned subsidiary of Neurotrope, Inc. ( Neurotrope ). On May 17, 2020, Neurotrope announced plans for the complete legal and structural separation of Synaptogenix from Neurotrope (the Spin-Off ).
The institution is unprofitable. This typically signals severe credit losses or a business in transition.
Traditional FCF and operating-margin metrics are not meaningful for financial institutions. Evaluate using net interest margin, credit quality, and capital ratios instead.
Profitability & Returns
Revenue (FY)
$299K
Net Income (TTM)
-$25M
▼ -125.1% YoY
Net Margin
—
P/E
—
Balance Sheet
Total Assets
$31M
Equity
$23M
Total Debt
$0.00
Cash & Equiv.
$4M
Continue Research